| CAS NO: | 109683-61-6 |
| 包装 | 价格(元) |
| 1mg | 询价 |
| 5mg | 询价 |
| 10mg | 询价 |
| 20mg | 询价 |
| Cas No. | 109683-61-6 |
| 别名 | 乌替普利,FPL 63547 |
| Canonical SMILES | O=C([C@@H]1SC(C(C)(C)C)=NN1C([C@@H](N[C@H](C(OCC)=O)CCC2=CC=CC=C2)C)=O)O |
| 分子式 | C22H31N3O5S |
| 分子量 | 449.56 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Utibapril is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activities. Utibapril significantly inhibits plasma, renal, and vascular ACE but not ventricular ACE activity. Utibapril (2 μg/kg/day) significantly inhibits vascular ACE activity, and Utibapril (250 μg/kg/day) results in a significant inhibition of plasma ACE. Furthermore, angiotensin I-induced decreases in coronary flow in the isolated heart are significantly inhibited after treatment with the higher doses of utibapril[1]. FPL 63547 is rapidly and extensively excreted as the diacid in the bile but appeared in the urine in negligible amounts[2]. [1]. Buikema H, et al. Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol. 1997 May;29(5):684-91. [2]. Carr RD, et al. Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the rat. Br J Pharmacol. 1990 May;100(1):90-4. |
| 维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |